was not inherent in the disclosed formulations and third involving the claim is not obvious the district court found that skilled artisans would not have thought that i could if you guys would work as a result of the claims ok you know it's we've had it not a huge part of that stems from the fact that a lot of the enablement cases like like the one you're referring to like the rest was in case the enablement issue was framed in terms of utility and  in a case like this where the functional language is in the claims actually speaks to effectiveness that can if you talk if you talk about whether the claims work it might sound like both the utility requirement as well between having you know conclusive experimental data and having no information and there is some line that can be drawn in between there where it's enough or it's not enough and that's one of the then in the context of the case i don't think you have to draw that line in this case because what we have here is no information of fact and there are some references to whether or not that then a person skilled in the art would have understood that they have this is that isn't that sufficient with no natural language in the written description  well i think there are some cases that are found that again in this case we have affirmative findings by the district court that there is no information in the specification about this new patient this effectiveness was not inherent in the formulation so you can't and impute it that way and we have affirmative findings that the person skilled in the art would not have thought this was going well except there is there is this is that appendix page eighty of her opinion and it's kind of confusing because it's not the written it's just i don't think i effective for treating pain and conditions like arthritis does that go to the whether they're really they're cute or is this something else or is your argument that the sites we can quibble we can just debate whether or not the site she gives really do what she says they do but in any of that what's your reaction to that so i would argue that this is something different terribly i think this goes to you till it is so  would have to double check on that your honor i'm not sure which expert this is but i can get th i think she just skipped over that part and said that doesn't require us to find otherwise but there's no explanation there there's no wrong there's nothing no attempt to reconcile the findings on the preceding two pages where she says the specification is no information about that aspect of the claims it's not right i think that is a finding of fact whether or not there's a disclosure in the specification and i think the dischord made that finding for us and i don't think it's been challenge here so s where the judge says if defendants point out this sort of patents do not address the efficacy of an could have p p i is through experimental testing data or other statements in the specification so there's no data there's not any other statement either and there's a similar statement  invention in this case it's intended purpose right that's inherent or for a useful purpose i think that's where the utility issue comes in so it's also been framed in terms of utility and in this case  have what is i think everyone agrees is a fairly straightforward simple pill structure that's disclosing the specification and i know that this report found that there was a really disputed that somebody skilled in there would know how to make him use that pill based on you know it's in the figures in specification somebody could make that and it would even if it wasn't disposed of having being there's no basis to find that it was effective for the un p p i effectiveness limitations somebody still there would still look at that and say well i know there's this and inflammatory in there i know what that does we normally give that within territories that's how it's presented here so it is going to treat pain and inflammation so it's going to have this reason beyond what we've just heard and as we move from the written description or grimm's i'm so sorry for your co counsel used up all your time we answer my question i asked him i certainly will call though my understanding was that it issued two years after this case again and eight years after the nine zero seven patent issue the point of the patent is preventing and said release unsafe and said really there is no other point the pat presents only one way to do this as explained by the inventor at trial the whole point of the idea here is to get acid inhibition before the administration of the inside there is no dispute that the two eighty five patent claims cover tablets that do not do this they cover caplets that release large amounts of approx and before any sort of commission the whole point of the idea here is undermined by releasing a large amount of the potential features not required but merely allow based upon the use of in prices i think the answer that question is that this specification is about one way to do something and that way is to requirement to disclaim or to negatively claim any possible feature that could be a problem for the invention that's the analysis that are arising from suggests but that's not the case at all here and i can give you a specific example why that is satisfied because this no affirmative no no claim element saying don't put our stake in this tablet because this invention has nothing to do with arsenic but it has everything to do with preventing crime safe and said release that's the whole good description of tablets that release a substantial amount of on the really substantial amount of research bloke ph three point five and these claims clearly read on that that's clearly not the invention if you look at the picture that's on page fifty three of the yellow well now they don't you're saying she's wrong because she concluded that the claims read that and i think the error that the district court made was that if you made a sharp distinction between limitations that were required and permitted that seemed to be a very important point for the district court which i think it's just a court got wrong i think that just records interpretation was that any element of a claim that's not required but permitted does not need written description at all and i think that's invention that's just hard to well for this particular patent i don't think it should be that difficult given that it doesn't have any purpose other than preventing unsafe instead loops that's the only disclosure of this pa had to appeal it here but this seems like we're talking about a plane instruction well i would disagree on respectfully i think that that's a stretch too far if you look at the words of this claim i'm not quite sure how dratch what i'm saying which he said no that this is a cl construction but i think we can just take the words of quinn and make them anything else what you would really have to do so i have this patent track the specification as it should have done is make these claims like the nine o seven questions you'd have to add in something like the end said coding term from the no seven which was source of the question the church while it raised while that i don't know that as i think that's a stretch too far are you going to suggest that it has no release at all y what exactly is the change that i would be proposed by as i said i think that's forcing the words to take on meaning to different from what they clearly are and that's not the regimen that was conducted in the seven different written description cases that we provided that issue could also apply to the i c u of medical case that was the case with the spite of elves the same question could be raised there why wasn't instead of excuse me that was a case before this court where are written description grounds because the claims were written in the absence of any type of a limitation of discussed spikes apparently the specification in that case talked about valves with spikes and this court decided that those claims were improper because they didn't well i'll start with p p i then i'll talk about the products and but i would like to first start with the concept of written description of what's required and i do believe the alcan case the court noted is controlling on this case in the sense of you must look at wh we need to get into those books which i'm sure you do by putting in of the claim so the question is for every claim limitation we need a written description what is there in the written description that deals with the addition of those to accept a column eight yep beginning in line five there's a description about what the therapeutic effect of the mounts are for purposes of this claim to invention it tells the reader those pho or at starting at column one you have in mind forty eight the inventor provides background about longer acting the downsides of those longer acting coded proton pump inhibitors and specifically i direct you to column two at line four through some of them which the district inventor is saying i'm doing something different from the prior art i want to actively raise and have and then the patent goes on as she noted and repeatedly talks about making that unco to people immediately release and inventors telling the public that that's going to work that method involves a coordinated participle composition that combines an agent that actively raises interest p age and by that meaning as further described in the pa points out the specifications teaching that immediate release is explicitly distinguished from the in terre coder formulation but to lay the absorption that the inventor is intending to issues she's just look she's relying on the testimony of experts who are saying what the specification well a lot why do we not get what they are saying because we are again on the point of treating pain in conditions like lot his last comment which is i'm not sure so i don't know whether she thought that was irrelevant or whatever it was michael what do you make of that if he concludes by saying i'm not sure at she didn't never to never do any good to be a problem she's talking about as i understand and call me on the column too is that depending on what kind of coding you're using including on how various bodies work the ability of the would be which relates when i'm coded p c i would be verified yeah but he's talking from us but we only know that amount just claim he's answering they're not looking at the specifications far as i can tell the context here they're just reading what the unlimited amount there just as there is no description for arsenic as discussed earlier or concrete or anything else that could be in compassed by a comprising term rather what's disclosed release is a defined term it's another limitation in the claim and i think that as i said before if you were to release a large amount of and say or an approximate first you were going to undermine the whole point of coordinated release that cannot be tolerated but that would be the result of the kind of destruction that they are suggesting this court up there at least half a dozen claims structure rules if you violate it by that claim construction and at the very beginning it should be clear to everyone that any retards indeed be the only safe manner the patent disclose this is the inventive matter inventive manner of release which is coordinating this so i do think that councils it's more than just being silent to characterize the alternative as being used in the next there in a different court record if that expression he had started the p b r i mean that may have been that would have been a factual question for the district court that's not the case we have here but that it's possible that it just that was enough but that's not what it says in this case and that's not the finding we have